^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Cutaneous Melanoma |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) + Imlygic (talimogene laherparepvec) (GM-CSF agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
02/19/2021
Excerpt:
...ipilimumab/T-VEC combination therapy is a category 2B recommendation, only listed as an option for second or subsequent-line therapy (not first-line therapy), and is not a preferred option.
